Today's Trend
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is receiving a favorable near-term boost from analyst optimism and a constructive view of its commercial strategy. The company’s shares remain near the middle of their 52-week range, while recent revenue growth and improving earnings expectations provide additional support.
- Wolfe Research upgraded MDGL to “Outperform” from “Peer Perform” and set a $605 price target. The target implies approximately 17.7% potential upside from the referenced price, signaling increased confidence in Madrigal’s commercial outlook and supporting investor sentiment. Benzinga report
- HC Wainwright raised its 2026 earnings forecasts. The firm now expects third-quarter 2026 EPS of $(0.10), versus $(1.05) previously, and fourth-quarter EPS of $0.85, versus $0.18. Its full-year 2026 forecast also improved to $(4.47) from $(7.07), while maintaining a “Buy” rating. These revisions suggest analysts expect Madrigal’s business to approach profitability faster than previously anticipated. MarketBeat analyst estimates
- A recent analysis described the launch environment for semaglutide as manageable and Madrigal’s pipeline strategy as disciplined. The view that the company can navigate competition from semaglutide while concentrating resources on its core opportunities may be reassuring to investors evaluating long-term growth and execution risk. Seeking Alpha analysis
- HC Wainwright continues to project a transition from losses in 2026 to positive EPS beginning in 2027, but its estimates remain dependent on successful commercialization and future execution.
- HC Wainwright reduced its longer-term EPS estimates. Forecasts were lowered for 2027 through 2030, including 2027 EPS to $8.32 from $11.78 and 2030 EPS to $77.98 from $93.68. Although the firm remains bullish, the cuts temper the valuation upside implied by the revised near-term estimates.